Market›Health Care›Biotechnology›Biotechnology
TSCAN THERAPEUTICS I

TCRX

$1.26Jul 16, 2021 – Apr 24, 2026
Health CareBiotechnology$59M
MVM
-$0.9M
TD Variance
-0.667

Every news event mapped to its market reaction — 119 events, 58 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2023-05-09+115.5%legalSEC EDGARTCRX 8-K: 1.01, 7.01 (SEC Filing)
2025-11-03-41.3%legalSEC EDGARTCRX 8-K: 2.05, 7.01, 8.01 (SEC Filing)
2025-11-03-41.3%newsInvesting.comTscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
2025-11-03-41.3%newsStock TitanTScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
2024-12-10-34.1%legalSEC EDGARTCRX 8-K: 7.01, 8.01 (SEC Filing)
2023-05-10+32.1%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2026-04-17+31.4%newsStock TitanTScan Therapeutics (NASDAQ: TCRX) seeks big boost in authorized shares at 2026 meeting - Stock Titan
2023-05-17-20.0%legalSEC EDGARTCRX 8-K: 8.01 and (SEC Filing)
2021-08-19-19.1%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2023-12-22+18.9%newsSeeking AlphaTScan Therapeutics director discloses purchase of 29,147 shares
2023-12-11-18.4%legalSEC EDGARTCRX 8-K: 7.01, 8.01 (SEC Filing)
2024-06-14-18.2%legalSEC EDGARTCRX 8-K: 5.02, 5.07 (SEC Filing)
2024-05-13+15.8%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.32, revenue of $0.56M
2024-05-13+15.8%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2023-03-31-14.6%legalSEC EDGARTCRX 8-K: 5.02, 7.01 (SEC Filing)
2024-03-22+13.6%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2022-05-09+13.5%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2022-08-10-12.9%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2025-11-26+12.1%legalSEC EDGARTCRX 8-K: 5.02 (SEC Filing)
2023-05-16-12.0%legalSEC EDGARTCRX 8-K: 8.01 and (SEC Filing)
2024-11-01+11.7%legalSEC EDGARTCRX 8-K: 1.01 and (SEC Filing)
2023-06-06+11.7%legalSeeking AlphaTScan gains as FDA clears studies for T cell therapy candidate
2024-04-16-11.5%expansionSeeking AlphaTScan Therapeutics announces launch of $125M proposed public offering
2024-04-16-11.5%legalSEC EDGARTCRX 8-K: 7.01, 8.01 (SEC Filing)
2021-12-02-9.2%legalSEC EDGARTCRX 8-K: 1.01, 2.03 (SEC Filing)
2026-03-04+9.0%earningsZacksTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
2026-03-04+9.0%newsGlobeNewswireTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-04+9.0%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M
2026-03-04+9.0%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2026-03-04+9.0%earningsYahoo FinanceTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
2026-03-04+9.0%newsGlobeNewswireTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
2026-03-04+9.0%earningsTradingViewTScan Therapeutics 10-K: $10.3M Collaboration Revenue, $(129.8)M Net Loss - TradingView
2025-05-06-8.9%earningsSeeking AlphaTScan Therapeutics GAAP EPS of $0.26
2025-05-06-8.9%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2025-08-12+8.5%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.28
2025-08-12+8.5%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2025-08-12+8.5%analystQuiver QuantitativeTCRX | TScan Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
2025-03-07-8.5%newsSeeking AlphaTScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025
2023-04-10-8.3%legalSEC EDGARTCRX 8-K: 5.02 and (SEC Filing)
2022-08-05+8.3%analystZacks Investment ResearchWhat is the current Price Target and Forecast for TScan Therapeutics (TCRX) - Zacks Investment Research
2021-11-26-8.2%analysteToroTCRX Stock Price | Analyst Target 6.00 & Consensus - eToro
2022-01-24+8.2%legalSEC EDGARTCRX 8-K: 8.01 and (SEC Filing)
2025-04-25-7.7%newsStock TitanTCRX Stock Price, News & Analysis - Stock Titan
2024-11-12-7.6%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M
2024-11-12-7.6%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2023-03-08-6.8%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2024-06-21-6.7%newsMLQ.aiTScan Therapeutics, Inc. Stock Splits | TCRX - MLQ.ai
2024-12-26+6.2%newsSeeking AlphaTScan Therapeutics announces ~$30M direct offering
2024-12-26+6.2%legalSEC EDGARTCRX 8-K: 1.01, 8.01 (SEC Filing)
2023-01-23-5.9%legalSEC EDGARTCRX 8-K: 8.01 and (SEC Filing)
2025-11-12-5.8%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.28, revenue of $2.51M
2025-11-12-5.8%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2025-11-12-5.8%earningsYahoo FinanceTScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
2022-03-09+5.6%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2026-02-06+5.6%earningsZacksRoivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
2026-02-25+5.4%earningsZacksRecursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
2026-02-25+5.4%newsGlobeNewswireTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2025-02-10-5.3%newsSeeking AlphaTScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
2023-06-16+5.3%legalSEC EDGARTCRX 8-K: 5.02, 5.07 (SEC Filing)
2022-09-03+5.1%analystTradingViewTCRX Forecast — Price Target — Prediction for 2027 - TradingView
2024-04-08+4.9%legalSEC EDGARTCRX 8-K: 8.01 and (SEC Filing)
2023-12-04+4.9%executiveSeeking AlphaTScan Therapeutics gets new technology chief
2026-02-11-4.8%newsZacksSutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
2025-07-11+4.5%newssimplywall.stGreat week for TScan Therapeutics, Inc. (NASDAQ:TCRX) institutional investors after losing 73% over the previous year - simplywall.st
2025-08-20+4.2%legalSEC EDGARTCRX 8-K: 5.02 (SEC Filing)
2023-08-10-4.2%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.51, revenue of $3.1M
2023-08-10-4.2%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2026-04-08-4.1%newsGlobeNewswireTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-04-08-4.1%newsStock TitanTScan to webcast Needham healthcare conference fireside chat - Stock Titan
2023-12-07-3.9%legalSEC EDGARTCRX 8-K: 5.02 and (SEC Filing)
2021-07-20-3.8%legalSEC EDGARTCRX 8-K: 5.02, 5.03 (SEC Filing)
2024-12-23-3.7%legalSEC EDGARTCRX 8-K: 1.01, 1.02, 2.03, 7.01 (SEC Filing)
2022-11-09-3.7%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2023-10-14+3.7%M&ASeeking AlphaTScan Therapeutics: That Recent Amgen Deal Is The Only Point Of Interest
2025-03-05+3.7%legalSeeking AlphaTScan Therapeutics files for $300M mixed securities shelf
2025-03-05+3.7%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.30, revenue of $0.67M
2025-03-05+3.7%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2026-02-26-3.5%legalGlobeNewswireTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
2026-02-26-3.5%newsStock TitanTScan readies pivotal T cell trial and new 2026 studies in hematologic cancers - Stock Titan
2023-05-26-3.4%legalSeeking AlphaTScan Therapeutics stock slides on pricing $140M securities offering
2023-05-31-3.3%legalSEC EDGARTCRX 8-K: 1.01, 8.01 (SEC Filing)
2023-05-31-3.3%legalSEC EDGARTCRX 8-K: 5.02, 7.01 (SEC Filing)
2022-09-12+3.3%legalSEC EDGARTCRX 8-K: 1.01, 2.03, 7.01 (SEC Filing)
2021-07-18-3.2%newsZacks Investment ResearchShould I buy TScan Therapeutics (TCRX) - Zacks Investment Research
2021-07-17-3.2%earningsMarketBeatTScan Therapeutics (TCRX) Stock Price, News & Analysis - MarketBeat
2021-07-17-3.2%earningsMarketBeatTScan Therapeutics (TCRX) Earnings Date and Reports 2026 - MarketBeat
2023-12-28-3.1%newsSeeking AlphaTScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value
2021-11-10+3.0%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2023-06-29-2.8%executiveSeeking AlphaTScan Therapeutics CFO resigns
2023-06-29-2.8%legalSEC EDGARTCRX 8-K: 5.02, 7.01 (SEC Filing)
2024-08-12-2.7%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.28, revenue of $0.5M
2024-08-12-2.7%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2026-02-12-2.6%earningsZacksAgios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
2023-08-14+2.6%earningsSeeking AlphaTScan Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
2024-11-21+2.5%legalSEC EDGARTCRX 8-K: 3.02 (SEC Filing)
2024-08-26-2.4%newsSeeking AlphaTScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
2023-11-09+2.2%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.24, revenue of $3.9M
2023-11-09+2.2%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2024-04-17-2.1%newsSeeking AlphaTScan Therapeutics prices upsized stock offering to raise $150 million
2024-04-17-2.1%legalSEC EDGARTCRX 8-K: 1.01, 2.02, 8.01 (SEC Filing)
2025-10-30+1.8%newsSeeking AlphaTScan Therapeutics, Inc. (TCRX) Presents at ACR Convergence 2025 - Slideshow
2022-05-31+1.7%legalSEC EDGARTCRX 8-K: 8.01 and (SEC Filing)
2024-01-29-1.5%executiveSeeking AlphaTScan Therapeutics appoints CFO
2024-01-29-1.5%legalSEC EDGARTCRX 8-K: 5.02 and (SEC Filing)
2023-08-29+1.3%legalSeeking AlphaTScan Therapeutics gets FDA's IND clearance for its fourth T cell therapy targeting solid tumors
2026-03-25+1.2%analystInsider MonkeyStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
2026-03-25+1.2%analystYahoo FinanceStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance
2022-07-07+1.1%legalSEC EDGARTCRX 8-K: 5.02 (SEC Filing)
2025-08-15-0.8%newsYahoo FinanceTScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely - Yahoo Finance
2026-04-23+0.4%earningsCổng thông tin điện tử tỉnh Tây NinhIs institutional money buying TScan Therapeutics (TCRX) stock | Q4 2025: Profit Exceeds Views - P/E Ratio - Cổng thông tin điện tử tỉnh Tây Ninh
2022-06-03+0.4%legalSEC EDGARTCRX 8-K: 5.02 and 5.07 (SEC Filing)
2026-04-02+0.4%legalSEC EDGARTCRX 8-K: 5.02 (SEC Filing)
2026-04-02+0.4%executiveTipRanksTScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
2023-07-25-0.3%legalSEC EDGARTCRX 8-K: 5.02 and (SEC Filing)
2025-05-18-0.1%newsIntellectia AITCRX Forecast — Price Prediction for 2026. Should I Buy TCRX? - Intellectia AI
2024-03-06+0.1%legalSeeking AlphaTScan Therapeutics tiles $300M mixed securities shelf
2024-03-06+0.1%earningsSeeking AlphaTScan Therapeutics GAAP EPS of -$0.21, revenue of $7.2M
2024-03-06+0.1%legalSEC EDGARTCRX 8-K: 2.02 and (SEC Filing)
2021-07-16—newsTradingViewTCRX Stock Price and Chart — NASDAQ:TCRX - TradingView
tickerdossier.comtickerdossier.substack.com